Generic Medicine Info
Indications and Dosage
Prophylaxis of migraine
Adult: In patients with at least 4 migraine days per month: 225 mg once monthly or 675 mg every 3 months, review treatment within 1st 3 months and regularly thereafter. When switching dosing regimens, the 1st dose of the new regimen should be administered on the next scheduled dosing date of the prior regimen.
Serious hypersensitivity.
Special Precautions
Patient with history of significant CV disease, vascular ischaemia or thrombotic events (e.g. cerebrovascular accident, TIA, deep vein thrombosis, pulmonary embolism). Pregnancy and lactation.
Adverse Reactions
Significant: Hypersensitivity reactions (e.g. anaphylaxis, angioedema, rash, pruritus, urticaria), immunogenicity.
General disorders and administration site conditions: Injection site reactions (e.g. pain, induration, erythema, pruritus, rash).
Mechanism of Action: Fremanezumab is a human monoclonal antibody. It selectively binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor. The exact mechanism by which it prevents migraine attacks is still unknown but is believed to be obtained by its modulating effect on the trigeminal system.
Absorption: Bioavailability: Approx 66%. Time to peak plasma concentration: 5-7 days.
Distribution: Volume of distribution: Approx 6 L.
Metabolism: Metabolised by enzymatic proteolytic into small peptides and amino acids.
Excretion: Elimination half-life: Approx 31 days.
Store between 2-8°C. Do not freeze. Protect from light.
MIMS Class
Antimigraine Preparations
ATC Classification
N02CD03 - fremanezumab ; Belongs to the class of calcitonin gene-related peptide (CGRP) antagonists preparations. Used to relieve migraine.
Ajovy 225 mg Solution for Injection in Pre-filled Pen (Teva UK Limited). MHRA. Accessed 07/12/2021.

Ajovy 225 mg Solution for Injection in Pre-filled Syringe (Teva UK Limited). MHRA. Accessed 07/12/2021.

Ajovy Injection (Teva Pharmaceuticals USA, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 07/12/2021.

Anon. Fremanezumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 07/12/2021.

Buckingham R (ed). Fremanezumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 07/12/2021.

Joint Formulary Committee. Fremanezumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 07/12/2021.

Disclaimer: This information is independently developed by MIMS based on Fremanezumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in